<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03985319</url>
  </required_header>
  <id_info>
    <org_study_id>YYPCT_YYD601_P1(2)</org_study_id>
    <nct_id>NCT03985319</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Assess the PK/PD of YYD601 20mg After Oral Administration if Healthy Adult Subjects (Phase1)</brief_title>
  <official_title>A Randomized, Open-label, Cross-over Design Clinical Trial to Assess the Pharmacokinetic/Pharmacodynamic Properties and Safety of YYD601 20mg After Oral Administration in Healthy Adult Subjects (Phase1)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yooyoung Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yooyoung Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinical Trial to Assess the PK/PD of YYD601 20mg After Oral Administration if Healthy Adult
      Subjects (Phase1)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate comparatively a characteristics and safety of the PK/PD of single/repeated oral
      administration YYD601 20mg and Nexium tab 20mg and the effects of food influence the PK/PD of
      YYD601 20mg in a healthy adults.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 10, 2019</start_date>
  <completion_date type="Anticipated">July 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">July 10, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>Integrated gastric acidity: Stomach acid test (24pH) on 1 day, 5 day, 11 day, 16 day</time_frame>
    <description>Cmax after single administration and repeated administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC</measure>
    <time_frame>Integrated gastric acidity: Stomach acid test (24pH) on 1 day, 5 day, 11 day, 16 day</time_frame>
    <description>AUC after single administration and repeated administration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC</measure>
    <time_frame>pH&gt;4(%): stomach acid test(24pH) on -1 day, 5 day, 11 day, 16 day and change in serum gastrin level on -1 day, 1day, 5 day</time_frame>
    <description>AUC after single administration and repeated administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>pH&gt;4(%): stomach acid test(24pH) on -1 day, 5 day, 11 day, 16 day and change in serum gastrin level on -1 day, 1day, 5 day</time_frame>
    <description>Tmax after single administration and repeated administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2</measure>
    <time_frame>pH&gt;4(%): stomach acid test(24pH) on -1 day, 5 day, 11 day, 16 day and change in serum gastrin level on -1 day, 1day, 5 day</time_frame>
    <description>t1/2 after single administration and repeated administration</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>GERD</condition>
  <arm_group>
    <arm_group_label>YYD601 20mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Esomeprazole IR 10mg + esomeprazole SR 10mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nexium tab 20mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Esomeprazole magnesium trihydrate 22.3mg. Astrazeneca</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YYD601 20mg</intervention_name>
    <description>Esomeprazole IR 10mg + Esomeprazole SR 10mg (Expected efficacy and effects: GERD)</description>
    <arm_group_label>Nexium tab 20mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nexium tab 20mg</intervention_name>
    <description>Esomeprazole magnesium trihydrate 22.3mg Effecacy and Effects: GERD and Antibiotics combined therapy to eradicate the Helicobacter pylori</description>
    <arm_group_label>YYD601 20mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy volunteers of over 19 years old at the time of screening.

          -  Volunteers weighing over 50 kg with ideal body weight (IBW) between -20% ~ 20%

          -  Subjects don't have congenital or chronic disease and is without pathologic symptom or
             finding on medical exam.

          -  Subjects evaluated eligible for the study based on the screening test results such as
             laboratory tests including serology, hematology, blood chemistry and urinalysis, etc
             and electrocardiogram(ECG).

          -  Subejctys who signed on the written informed consent form and comply with study
             requirements after listening adn fully understanding the details of this study.

        Exclusion Criteria:

          -  Who has hyper sensitivity reaction about other drugs, ingredients, components of
             investigator product or compound of benzimidazole.

          -  Who has genetic problem like fructose tolerance, glucose-galctose absorption,
             deficiency or sucrase-iso maltase deficiency.

          -  Medical history or evidence (hepatobiliary, renal, cardiovascular, endocrine,
             respiratory, gastrointestinal, hemato-oncology, central nervous system, psychiatric
             and musculoskeletal system) that can affect absorption, distribution, metabolism and
             excretion of a given drug.

          -  Subject who has over 141mmHg or under 89mmHg of systolic pressure or over 95mmHg of
             diastolic pressure in vital sign or over 100 times/min of pulse rate.

          -  Who has active liver disease, (AST, ALT, total bilirubin &gt; 2 x LNR), (BUN, creatinine
             &gt;1.5 x LNR) or clinically abnoramal result at screening test.

          -  Creatinine clearance &lt; 80 mL/min (calcaulated by Cockcroft-Gault formula using serum
             creatinine)

          -  History of gastrointestinal disease (e.g., Crohns disease, active peptic ulcer) or
             gastrointestinal surgery that may affect the absorption of the study drug (excluding
             simple appendectomy or herniorrhaphy)

          -  Treatments for peptic ulcer, esophageal disease, Zollinger-Ellison syndrome diagnosis
             therapy or clinically related histories within 3 months prior to the first dose.

          -  Positive 13C-urea breath test

          -  A history of serious trauma within 4 weeks, or resection operation (exculding simiple
             appendectomy or herniorrhaphy) and/or relevant history or laboratory or clinical
             findings indicative of acute disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Min-Kyung Kwon</last_name>
    <phone>+82-6202-7121</phone>
    <email>monica.kim@yypharm.co.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ye Rum Kim</last_name>
    <phone>+82-6202-7121</phone>
    <email>monica.kim@yypharm.co.kr</email>
  </overall_contact_backup>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>May 29, 2019</study_first_submitted>
  <study_first_submitted_qc>June 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 13, 2019</study_first_posted>
  <last_update_submitted>June 11, 2019</last_update_submitted>
  <last_update_submitted_qc>June 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esomeprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

